ENNODC

We design and develop a novel class of immunotherapy antibodies combining the precision of immune checkpoint modulators with the long-term impact of vaccines.

EnnoDC is a clinical-stage biotech that designs and develops DC engagers that combine antigen-priming with controlled activation of dendritic cells in vivo to induce a precise, broad and durable immune response.

Partnerships

 

  

  

 

  

  

 

  

  

Clients